Search research articles
Contact Us
Filters
Showing results (11-20 of 48) with videos related to
Page
of 5
Sort By:
Leukemia & Lymphoma
|
January 8, 2013
Oral clofarabine for relapsed/refractory non-Hodgkin lymphomas: results of a phase 1 study
Jeremy S Abramson, Ronald W Takvorian, David C Fisher, et al.
Journal of Cancer Education : the Official Journal of the American Association for Cancer Education
|
October 21, 2017
Developing a Novel Model to Improve Research and care for Cancer Survivors: a Feasibility Study
Shoshana M Rosenberg, Jennifer A Ligibel, Jeffrey A Meyerhardt, et al.
British Journal of Haematology
|
January 3, 2013
Prognostic factors for patients with diffuse large B cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation in the positron emission tomography era
Philippe Armand, Sarah Welch, Haesook T Kim, et al.
Blood
|
January 10, 2015
Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression
Eric D Jacobsen, Jeff P Sharman, Yasuhiro Oki, et al.
The Oncologist
|
December 30, 2017
Autologous Stem Cell Transplantation in Elderly Lymphoma Patients in Their 70s: Outcomes and Analysis
Lova Sun, Shuli Li, Areej El-Jawahri, et al.
Leukemia & Lymphoma
|
December 3, 2011
Risk factors for development of pneumonitis after high-dose chemotherapy with cyclophosphamide, BCNU and etoposide followed by autologous stem cell transplant
Andrew A Lane, Philippe Armand, Yang Feng, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 22, 2026
Duvelisib Induces Deep Responses in PTCL: Final Results of the Phase 2 PRIMO Trial of Duvelisib in Relapsed/Refractory Peripheral T-Cell Lymphoma
Neha Mehta-Shah, Pier Luigi Zinzani, Eric D Jacobsen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 16, 2011
Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia
Philip C Amrein, Eyal C Attar, Tak Takvorian, et al.
British Journal of Haematology
|
January 6, 2016
A phase 2 study of Rituximab-Bendamustine and Rituximab-Cytarabine for transplant-eligible patients with mantle cell lymphoma
Philippe Armand, Robert Redd, Jad Bsat, et al.
Leukemia & Lymphoma
|
October 17, 2018
Ofatumumab plus high dose methylprednisolone followed by ofatumumab plus alemtuzumab to achieve maximal cytoreduction prior to allogeneic transplantation for 17p deleted or TP53 mutated chronic lymphocytic leukemia<sup>.</sup>
Matthew S Davids, Haesook T Kim, Lijian Yu, et al.
Page
of 5
Search research articles
Search
Showing results (11-20 of 48) with videos related to
Sort By:
Page
of 5
Leukemia & Lymphoma
|
January 8, 2013
Oral clofarabine for relapsed/refractory non-Hodgkin lymphomas: results of a phase 1 study
Jeremy S Abramson, Ronald W Takvorian, David C Fisher, et al.
Journal of Cancer Education : the Official Journal of the American Association for Cancer Education
|
October 21, 2017
Developing a Novel Model to Improve Research and care for Cancer Survivors: a Feasibility Study
Shoshana M Rosenberg, Jennifer A Ligibel, Jeffrey A Meyerhardt, et al.
British Journal of Haematology
|
January 3, 2013
Prognostic factors for patients with diffuse large B cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation in the positron emission tomography era
Philippe Armand, Sarah Welch, Haesook T Kim, et al.
Blood
|
January 10, 2015
Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression
Eric D Jacobsen, Jeff P Sharman, Yasuhiro Oki, et al.
The Oncologist
|
December 30, 2017
Autologous Stem Cell Transplantation in Elderly Lymphoma Patients in Their 70s: Outcomes and Analysis
Lova Sun, Shuli Li, Areej El-Jawahri, et al.
Leukemia & Lymphoma
|
December 3, 2011
Risk factors for development of pneumonitis after high-dose chemotherapy with cyclophosphamide, BCNU and etoposide followed by autologous stem cell transplant
Andrew A Lane, Philippe Armand, Yang Feng, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 22, 2026
Duvelisib Induces Deep Responses in PTCL: Final Results of the Phase 2 PRIMO Trial of Duvelisib in Relapsed/Refractory Peripheral T-Cell Lymphoma
Neha Mehta-Shah, Pier Luigi Zinzani, Eric D Jacobsen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 16, 2011
Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia
Philip C Amrein, Eyal C Attar, Tak Takvorian, et al.
British Journal of Haematology
|
January 6, 2016
A phase 2 study of Rituximab-Bendamustine and Rituximab-Cytarabine for transplant-eligible patients with mantle cell lymphoma
Philippe Armand, Robert Redd, Jad Bsat, et al.
Leukemia & Lymphoma
|
October 17, 2018
Ofatumumab plus high dose methylprednisolone followed by ofatumumab plus alemtuzumab to achieve maximal cytoreduction prior to allogeneic transplantation for 17p deleted or TP53 mutated chronic lymphocytic leukemia<sup>.</sup>
Matthew S Davids, Haesook T Kim, Lijian Yu, et al.
Page
of 5